These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35512587)

  • 1. High tumor mutational burden (TMB) identifies a microsatellite stable pancreatic cancer subset with prolonged survival and strong anti-tumor immunity.
    Karamitopoulou E; Andreou A; Wenning AS; Gloor B; Perren A
    Eur J Cancer; 2022 Jul; 169():64-73. PubMed ID: 35512587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
    Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.
    Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C
    Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.
    Singhi AD; George B; Greenbowe JR; Chung J; Suh J; Maitra A; Klempner SJ; Hendifar A; Milind JM; Golan T; Brand RE; Zureikat AH; Roy S; Schrock AB; Miller VA; Ross JS; Ali SM; Bahary N
    Gastroenterology; 2019 Jun; 156(8):2242-2253.e4. PubMed ID: 30836094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.
    Fabrizio DA; George TJ; Dunne RF; Frampton G; Sun J; Gowen K; Kennedy M; Greenbowe J; Schrock AB; Hezel AF; Ross JS; Stephens PJ; Ali SM; Miller VA; Fakih M; Klempner SJ
    J Gastrointest Oncol; 2018 Aug; 9(4):610-617. PubMed ID: 30151257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.
    Salem ME; Bodor JN; Puccini A; Xiu J; Goldberg RM; Grothey A; Korn WM; Shields AF; Worrilow WM; Kim ES; Lenz HJ; Marshall JL; Hall MJ
    Int J Cancer; 2020 Nov; 147(10):2948-2956. PubMed ID: 32449172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors.
    Xavier CB; Lopes CDH; Awni BM; Campos EF; Alves JPB; Camargo AA; Guardia GDA; Galante PAF; Jardim DL
    Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers.
    Palmeri M; Mehnert J; Silk AW; Jabbour SK; Ganesan S; Popli P; Riedlinger G; Stephenson R; de Meritens AB; Leiser A; Mayer T; Chan N; Spencer K; Girda E; Malhotra J; Chan T; Subbiah V; Groisberg R
    ESMO Open; 2022 Feb; 7(1):100336. PubMed ID: 34953399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic profile and clinical features of MSI-H and TMB-high pancreatic cancers: real-world data from C-CAT database.
    Sakakida T; Ishikawa T; Doi T; Morita R; Kataoka S; Miyake H; Yamaguchi K; Moriguchi M; Sogame Y; Yasuda H; Iwasaku M; Konishi H; Takayama K; Itoh Y
    J Gastroenterol; 2024 Feb; 59(2):145-156. PubMed ID: 38006445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy.
    Bao X; Zhang H; Wu W; Cheng S; Dai X; Zhu X; Fu Q; Tong Z; Liu L; Zheng Y; Zhao P; Fang W; Liu F
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1/PD-L1-Associated Immunoarchitectural Patterns Stratify Pancreatic Cancer Patients into Prognostic/Predictive Subgroups.
    Karamitopoulou E; Andreou A; Pahud de Mortanges A; Tinguely M; Gloor B; Perren A
    Cancer Immunol Res; 2021 Dec; 9(12):1439-1450. PubMed ID: 34526323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High tumor mutation burden (TMB) in microsatellite stable (MSS) colorectal cancers: Diverse molecular associations point to variable pathophysiology.
    Voutsadakis IA
    Cancer Treat Res Commun; 2023; 36():100746. PubMed ID: 37494750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-Infiltrating Lymphocytes, Tumor Mutational Burden, and Genetic Alterations in Microsatellite Unstable, Microsatellite Stable, or Mutant
    Keshinro A; Vanderbilt C; Kim JK; Firat C; Chen CT; Yaeger R; Ganesh K; Segal NH; Gonen M; Shia J; Stadler Z; Weiser MR
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness.
    Quintanilha JCF; Storandt MH; Graf RP; Li G; Keller R; Lin DI; Ross JS; Huang RSP; Schrock AB; Oxnard GR; Chakrabarti S; Mahipal A
    JCO Precis Oncol; 2023 Jul; 7():e2300092. PubMed ID: 37410975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.
    Valero C; Lee M; Hoen D; Zehir A; Berger MF; Seshan VE; Chan TA; Morris LGT
    JAMA Oncol; 2021 May; 7(5):739-743. PubMed ID: 33599686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of Microsatellite Instability in Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Lupinacci RM; Goloudina A; Buhard O; Bachet JB; Maréchal R; Demetter P; Cros J; Bardier-Dupas A; Collura A; Cervera P; Scriva A; Dumont S; Hammel P; Sauvanet A; Louvet C; Delpéro JR; Paye F; Vaillant JC; André T; Closset J; Emile JF; Van Laethem JL; Jonchère V; Abd Alsamad I; Antoine M; Rodenas A; Fléjou JF; Dusetti N; Iovanna J; Duval A; Svrcek M
    Gastroenterology; 2018 Mar; 154(4):1061-1065. PubMed ID: 29158190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy.
    Goodman AM; Sokol ES; Frampton GM; Lippman SM; Kurzrock R
    Cancer Immunol Res; 2019 Oct; 7(10):1570-1573. PubMed ID: 31405947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Large-Scale Cancer Genomic Analysis Reveals Significant Disparities between Microsatellite Instability and Tumor Mutational Burden.
    Choi J; Park KH; Kim YH; Sa JK; Sung HJ; Chen YW; Chen Z; Li C; Wen W; Zhang Q; Shu XO; Zheng W; Kim JS; Guo X
    Cancer Epidemiol Biomarkers Prev; 2024 May; 33(5):712-720. PubMed ID: 38393316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.